NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies
about
Role of endoplasmic reticulum stress in drug-induced toxicityMultiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategiesRole of dietary polyphenols in the management of peptic ulcerGastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defenceIn vivo imaging reveals PKA regulation of ERK activity during neutrophil recruitment to inflamed intestines.Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury.Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis.Understanding and modulating mammalian-microbial communication for improved human health.Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota.NSAID enteropathy and bacteria: a complicated relationship.Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage.Toll-Like Receptor 4 Wild Type Homozygozity of Polymorphisms +896 and +1196 Is Associated with High Gastrin Serum Levels and Peptic Ulcer Risk.The influence of non-steroidal anti-inflammatory drugs on the gut microbiomeThe microbiota-derived metabolite indole decreases mucosal inflammation and injury in a murine model of NSAID enteropathy.Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokineticsMechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.Polypharmacy of osteoarthritis: the perfect intestinal storm.Histopathological changes in the gastrointestinal tract due to drugs: an update for the surgical pathologist (part I of II).Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges.Environmental and NSAID-enteropathy: dysbiosis as a common factor.Recent developments in chimeric NSAIDs as safer anti-inflammatory agents.Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and heme oxygenase 1 induction.A novel pH-controlled hydrogen sulfide donor protects gastric mucosa from aspirin-induced injury.Non-cytochrome P450-mediated bioactivation and its toxicological relevance.Gata4 is critical to maintain gut barrier function and mucosal integrity following epithelial injury.The non-invasive exfoliated transcriptome (exfoliome) reflects the tissue-level transcriptome in a mouse model of NSAID enteropathy.How close are we to developing enteric-protective drugs against non-steroidal anti-inflammatory drug-induced small intestinal injury? New mechanistic insight from preclinical models.Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users.Non-steroidal anti-inflammatory drug-induced enteropathy.GPR55 regulates intraepithelial lymphocyte migration dynamics and susceptibility to intestinal damage.Role of enterohepatic recirculation in drug disposition: cooperation and complications.FFA3 Activation Stimulates Duodenal Bicarbonate Secretion and Prevents NSAID-Induced Enteropathy via the GLP-2 Pathway in Rats.Activation of intestinal GR-FXR and PPARα-UGT signaling exacerbates ibuprofen-induced enteropathy in mice.Phenylbutazone induces equine glandular gastric disease without decreasing prostaglandin E2 concentrations.Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.H2S confers colonoprotection against TNBS-induced colitis by HO-1 upregulation in rats.Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits.
P2860
Q26765518-8195761B-ECD2-472E-8FE9-FF4AF7E8B512Q27000132-9C992416-9A5D-410E-844C-34E221D47FD6Q28088459-D744DF54-DBB4-4AA1-9950-B94752F2578AQ28482202-97946D3A-B95D-423C-9EBF-3596EA859B4EQ33702929-6090A0D4-AF92-4032-BBAD-4D985889AE55Q34226230-4680B0A4-B1D4-484B-8A48-E0843B47B2B3Q34606022-87BDE663-7AA2-4762-B93F-452C36B449A9Q35026463-4CCD3483-AF67-408B-95E1-DB1729315BECQ35314338-8C49FB64-C529-473E-B36F-34B31AFB3066Q35540435-52DD70A5-5AD5-47D6-B5DE-B8482762E1CDQ35660108-FC61D148-D331-48C1-B14B-A5111069EFACQ35687790-F2056B96-6190-447A-A95B-C21D3CDF0E1DQ35813554-5F3FFBB9-16AD-450D-87C5-05FE10A7C5B2Q37082691-E05E1606-E5CD-4750-BB42-83923C3062EAQ37679135-95C23BC3-6835-4D73-AB58-17690F1117CFQ38097424-565F2956-FB33-4F19-981F-6AC72112E6CFQ38124006-244E512A-2221-4F70-8300-BF45A30F9D1EQ38136048-3E2BB15E-6653-4471-87DE-22F5E90EA5D5Q38155495-87CEA4AA-6B25-4B9B-9FF0-6482BDB4B354Q38188487-6510FCF3-7946-4163-BD6E-BD8FF62472A5Q38260626-A6A065AB-9390-474B-841F-91DBA94BFBF8Q38438986-0A79B649-420E-4234-86EB-419AC9C7C0DDQ38733697-B3B68ADD-235F-41A1-A55F-88E7DF21CA0FQ38929936-3980EEB7-9A30-4676-A5F7-9E97B7B03A7AQ40458744-B2E9CED3-6F06-447B-A0A4-83897DAD61E1Q42778368-0FA69CEC-9EE6-4289-817C-720B9C0C841BQ43609300-4129D98B-EFCF-46FB-82D6-1C7608EB05B0Q45262131-5336E1CA-3B40-4F2E-8F6C-2A00EFB0BDC5Q45400230-64375998-58A7-404C-BE1D-336609C1A2E0Q46146528-C56D99D2-21C9-4BAD-B72B-57CD11B9A579Q46578287-3BF7F55B-6707-405E-8C8B-162E2063541FQ46883506-1935D744-1C85-4E92-A843-96B38DB2CEC8Q48149341-38EDDBD4-A9A6-4433-8495-595D8679BA3CQ48284277-D9815E54-33ED-4D80-AFFB-E4B812614C52Q50870345-CB4D80CF-31D0-484C-99C7-CCD14BD0C697Q53128579-2169C646-15FC-42AC-9EA5-DBC7D29C4631Q55071130-72DDBC38-ABB5-47D1-B557-F0B800FDDA37
P2860
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NSAID gastropathy and enteropa ...... distinct prevention strategies
@en
NSAID gastropathy and enteropa ...... istinct prevention strategies.
@nl
type
label
NSAID gastropathy and enteropa ...... distinct prevention strategies
@en
NSAID gastropathy and enteropa ...... istinct prevention strategies.
@nl
prefLabel
NSAID gastropathy and enteropa ...... distinct prevention strategies
@en
NSAID gastropathy and enteropa ...... istinct prevention strategies.
@nl
P2860
P1476
NSAID gastropathy and enteropa ...... distinct prevention strategies
@en
P2093
John L Wallace
P2860
P356
10.1111/J.1476-5381.2011.01509.X
P407
P577
2012-01-01T00:00:00Z